Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis

Table 2 Baseline factors associated with the efficacy of Tofacitinib at week 8

Variable	Univariate analyses			Multivariate analyses
	Non-responder (n = 34)	Responder (n = 67)	P value	Odds ratio	95%CI	P value
Age, years, median (IQR)	32.5 (27.5, 46.0)	37.0 (28.0, 47.5)	0.27	1.02	0.99-1.05	0.28
Sex (M/F), n	20/14	40/27	1.00
Baseline partial Mayo score, median (IQR)	7.0 (5.3, 8.0)	5.0 (4.0, 7.0)	< 0.001	0.61	0.45-0.82	0.001
Disease duration, years, median (IQR)	6.2 (1.7, 9.9)	4.5 (1.6, 10.0)	0.84
Disease extent, n (%)
Left-sided colitis	8 (23.5)	10 (14.9)
Extensive colitis	26 (76.5)	57 (85.1)	0.29
Family history of IBD, n (%)	3 (8.8)	4 (6.0)	0.69
Current smoker, n (%)	5 (14.7)	9 (13.4)	1.00
Intractability (dependent/refractory), n	16/18	32/33	1.00
Albumin, g/dL, median (IQR)	3.9 (3.5, 4.3)	3.9 (3.6, 4.2)	0.88
C-reactive protein, mg/dL, median (IQR)	0.2 (0.1, 0.7)	0.3 (0.1, 1.1)	0.49
White blood cells, /μL, median (IQR)	6660.0 (5107.5, 8415.0)	7260.0 (5760.0, 9460.0)	0.15	1.00	1.00-1.00	0.17
Hemoglobin, g/dL, median (IQR)	12.4 (11.1, 13.7)	12.3 (11.2, 14.0)	1.00
Baseline systemic corticosteroid use, n (%)	8 (23.5)	15 (22.4)	1.00
Previous immunomodulator, n (%)	24 (70.6)	46 (68.7)	1.00
Previous tacrolimus, n (%)	11 (32.4)	20 (29.9)	0.82
Previous biologics, n (%)
Previous anti TNF-α agent	22 (64.7)	41 (61.2)	0.83
Previous vedolizumab	4 (11.8)	7 (10.4)	1.00

CI: Confidence interval; IBD: Inflammatory bowel disease; IQR: Interquartile range; TNF-α: Tumor necrosis factor α.